ÂÜÀòÂÒÂ×

John Craighead, Ph.D. is an experienced executive in the biotech and biopharmaceutical sectors, currently serving as Chief Operating Officer and Chief Financial Officer at HALO Precision Diagnostics since May 2023, where the focus is on integrating advanced imaging with molecular diagnostics for early disease detection. Prior roles include leadership positions at Elpiscience Biopharmaceuticals, Inc. as Chief Financial Officer and Head of Corporate Development, and GRAIL, Inc., where responsibilities included Vice President of Strategy, Corporate Development & Investor Relations. John has also held significant positions at Atara Biotherapeutics, Sanofi, and Human Genome Sciences, among others. Education includes a Doctor of Philosophy in Cell Biology from Scripps Research and a Bachelor of Arts in Chemistry and Molecular Biology from St. Olaf College.